Reduction of cross-shareholdings
First written in FY2019. 6 of 7 entries say "Advanced", first in FY2020. Latest entry: FY2026.
- FY2026AdvancedAnnual report
「Following a review of 26 listed shares held as of the end of March 2025, considering transaction status, share prices and dividends, among other factors, the company sold all of 2 holdings and part of 3 holdings in FY2025.」
The company reviewed 26 strategic equity holdings and, in FY2025, sold all of 2 holdings and part of 3 holdings. - FY2025AdvancedAnnual report
「The company evaluated 2 items concerning the rationality of the purpose of holding the shares and 2 items concerning economic rationality. Based on the results, it reviewed 27 listed shares held as of the end of March 2024, considering transaction status, share prices and dividends, among other factors, and sold all of 1 holding and part of another in FY2024.」
The company reviewed 27 strategic equity holdings and, in FY2024, sold all of 1 holding and part of another. It also made an additional investment in Capricor Therapeutics to maintain and strengthen its sales partnership. - FY2024AdvancedAnnual report
「Following a review of 26 listed shares held as of the end of March 2023, considering transaction status, share prices and dividends, among other factors, the company sold part of 1 holding in FY2023.」
The company reviewed 26 strategic equity holdings and partially sold 1 holding in FY2023. - FY2023AdvancedAnnual report
「The company evaluated 2 items concerning the rationality of the purpose of holding the shares and 2 items concerning economic rationality. Based on the results, it reviewed 28 listed shares held as of the end of March 2022, considering transaction status, share prices and dividends, among other factors, and sold 2 holdings in FY2022.」
The company reviewed 28 strategic equity holdings and sold 2 in FY2022. - FY2021AdvancedAnnual report
「The company evaluated 2 items concerning the rationality of the purpose of holding the shares and 2 items concerning economic rationality. Based on the results, it reviewed 33 listed shares held as of the end of March 2020, considering transaction status, share prices and dividends, among other factors, and sold 4 holdings in FY2020.」
The company reviewed 33 strategic equity holdings and sold 4. This represents progress from the sale of 3 holdings in the previous fiscal year. - FY2020AdvancedAnnual report
「The company evaluated 2 items concerning the rationality of the purpose of holding the shares and 2 items concerning economic rationality. Based on the results, it reviewed 36 listed shares held as of the end of March 2019, considering transaction status, share prices and dividends, among other factors, and sold 3 holdings in FY2019.」
Under its policy of reducing strategic equity holdings, the company sold 3 of the 36 holdings reviewed, for sale proceeds of ¥1.34 billion. - FY2019First statedAnnual report
「In FY2019, the Board of Directors decided to sell 3 holdings. A reduction of approximately ¥1.5 billion at market value was expected.」
Following a review of 36 strategic equity holdings, the company first specified a policy of selling 3 holdings and reducing market value by approximately ¥1.5 billion.